SecurityRDUS / Radius Health, Inc. (750469207)
IndustryPharmaceutical Preparations
Common Shares Outstanding45,458,502 shares (as of 2018-03-31)
Total Insiders42
Total Directors12
Total Officers11

Stock Insider Trading (from SEC Form 4)

Radius Health, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

RDUS / Radius Health, Inc. insiders include Dere Willard H, BB BIOTECH AG, MPM BIOVENTURES III LLC, MPM BioVentures IV GP LLC, MPM BIOVENTURES III GP L.P., HENNER DENNIS, Snow David P., Carmona Jose, and Hoiland Jesper Kelly Joseph Francis, Purandare Dinesh, Fitzpatrick Lorraine A., Ward Robert, Hattersley Gary, GALAKATOS NICHOLAS, Muenchbach Martin, Graves Kurt, WHEELER KURT, Harvey Brian Nicholas, Hatzis-Schoch Brent, Hughes Owen, MPM Bio IV NVS Strategic Fund LP, MPM BioVentures IV LLC, MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC, Rosenberg Anthony, Scopa James Paul, Foley Todd, Roychowdhury Debasish, STEINMETZ MICHAEL, GADICKE ANSBERT, KAILIAN VAUGHN M, MPM BIOVENTURES III L.P., SIMON NICHOLAS J III, AUERBACH ALAN H, EVNIN LUKE, GARNIER JEAN PIERRE, MPM BIOVENTURES III GMBH & CO. Beteiligungs KG, MPM BIOVENTURES III-QP L.P., FRIEDMAN CATHY, Williams Gregory C., MPM BIOVENTURES III PARALLEL FUND, L.P., BIOTECH GROWTH N V, .

Insider Roster

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Form Insider Code 10b-5 Direct Share
Post Value
2018-06-11 4 BIOTECH GROWTH N V P D 27.3567 50,000 6,200,913 169,636,517
2018-05-23 4 BIOTECH GROWTH N V P D 28.908 40,000 6,150,913 177,810,593
2018-05-21 4 BIOTECH GROWTH N V P D 29.273 60,000 6,110,913 178,884,756
2018-04-19 4 BIOTECH GROWTH N V P D 33.7984 40,000 6,050,913 204,511,178
2018-04-12 4 BIOTECH GROWTH N V X D 14.004 107,114 6,010,913
2018-04-05 4 BIOTECH GROWTH N V P D 36.5769 50,000 5,903,799 215,942,666
2018-03-02 4 BIOTECH GROWTH N V P D 32.5181 80,000 5,853,799 190,354,421
2018-02-09 4 BIOTECH GROWTH N V P D 34.3835 75,000 5,773,799 198,523,418
2017-11-14 4 BIOTECH GROWTH N V P D 26.2478 50,000 5,698,799 149,580,936
2017-11-10 4 Hatzis-Schoch Brent P D 28.0893 1,778 2,278 63,987
2017-11-07 4 Hoiland Jesper P D 29.0368 6,800 12,900 374,575
2017-11-03 4 BIOTECH GROWTH N V P D 29.1515 50,000 5,648,799 164,670,964
2017-10-26 4 BIOTECH GROWTH N V P D 30.951 50,000 5,598,799 173,288,428
2017-10-25 4 BIOTECH GROWTH N V P D 32.8483 50,000 5,548,799 182,268,614
2017-09-15 4 Hoiland Jesper P D 32.7227 6,100 6,100 199,608
2017-09-14 4 Carmona Jose P D 32.8343 3,000 3,000 98,503
2017-09-14 4 BIOTECH GROWTH N V P D 32.9445 50,000 5,498,799 181,155,184
2017-09-13 4 BIOTECH GROWTH N V P D 33.7075 100,000 5,448,799 183,665,392
2017-09-12 4 BIOTECH GROWTH N V P D 35.4164 50,000 5,348,799 189,435,205
2017-09-05 4 BIOTECH GROWTH N V P D 36.7525 50,000 5,298,799 194,744,110
2017-08-16 4 BIOTECH GROWTH N V P D 35.9756 60,000 5,248,799 188,828,693
2017-08-10 4 BIOTECH GROWTH N V P D 34.26 75,000 5,188,799 177,768,254
2017-08-09 4 BIOTECH GROWTH N V P D 35.6737 75,000 5,113,799 182,428,131
2017-05-30 4 BIOTECH GROWTH N V P D 34.2087 40,000 5,038,799 172,370,763
2017-05-25 4 BIOTECH GROWTH N V P D 36.2505 40,000 4,998,799 181,208,963
2017-05-18 4 BIOTECH GROWTH N V P D 34.4069 50,000 4,958,799 170,616,901
2017-05-17 4 BIOTECH GROWTH N V P D 32.9812 18,000 4,908,799 161,898,082
2017-05-16 4 BIOTECH GROWTH N V P D 33.925 17,000 4,890,799 165,920,356
2017-05-12 4 BIOTECH GROWTH N V P D 33.9997 15,000 4,873,799 165,707,704
2017-05-09 4 BIOTECH GROWTH N V P D 35.9296 50,000 4,858,799 174,574,705
2017-05-08 4 BIOTECH GROWTH N V P D 35.5978 22,800 4,808,799 171,182,665
2017-05-05 4 BIOTECH GROWTH N V P D 35.5477 20,600 4,785,999 170,131,257
2017-05-02 4 BIOTECH GROWTH N V P D 33.9056 75,000 4,765,399 161,573,712
2017-05-01 4 BIOTECH GROWTH N V P D 35.3907 150,000 4,690,399 165,996,504
2017-04-25 4 Harvey Brian Nicholas M D 2.74 39,616 76,189
2017-03-21 4 BIOTECH GROWTH N V P D 35.8325 50,000 4,540,399 162,693,847
2017-03-20 4 Harvey Brian Nicholas M D 2.05 23,416 36,573
2017-03-17 4 BIOTECH GROWTH N V P D 38.4083 30,000 4,490,399 172,468,592
2017-03-15 4 BIOTECH GROWTH N V P D 39.956 44,469 4,460,399 178,219,702
2017-03-14 4 BIOTECH GROWTH N V P D 39.9993 17,252 4,415,930 176,634,109
2017-03-10 4 BIOTECH GROWTH N V P D 39.1673 38,279 4,398,678 172,284,341
2016-10-25 4 Ward Robert M D 7.8 10,000 15,000
2016-09-27 4 MPM BIOVENTURES III LLC J I -1,229,902 2,459,804
2016-09-27 4 GALAKATOS NICHOLAS J I -1,229,902 2,459,804
2016-09-27 4 GADICKE ANSBERT J I -1,943,751 3,887,502
2016-09-27 4 EVNIN LUKE J I -1,943,751 3,887,502
2016-09-27 4 MPM BioVentures IV LLC J I -713,849 1,427,698
2016-01-25 4 Fitzpatrick Lorraine A. P D 37.97 100 200 7,594
2015-11-25 4 Fitzpatrick Lorraine A. P D 60.595 100 100 6,060
2016-01-22 4 BIOTECH GROWTH N V P D 31.6658 38,259 4,360,399 138,075,523
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)
RDUS: Radius Health Analysis and Research Report

2018-05-04 - Asif

Overview Radius Health is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. In April 2017, its first commercial product, TYMLOSTM (abaloparatide) injection, was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In May 2017, the company commenced U.S. commercial sales of TYMLOS and, as of February 2018, TYMLOS was available and covered for approximately 259 million U.S. insured lives, representing approximately 86% of U.S. insured lives. In May 2017, the company also announced positive top-line results from its completed 24-month ACTIVExtend clinical trial for TYMLOS, which met all of ...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Why Is Radius Health (RDUS) Down 9.7% Since its Last Earnings Report?

2018-06-11 zacks
It has been about a month since the last earnings report for Radius Health, Inc. (RDUS - Free Report) . Shares have lost about 9.7% in that time frame. (34-0)

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

2018-05-31 seekingalpha
FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme. (666-4)

Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

2018-05-22 seekingalpha
My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received thus far. (688-11)